Evidence map›Paper›PMID 33893702›Full record

ArticleGenes to cells : devoted to molecular & cellular mechanisms2021

The structure of POMGNT2 provides new insights into the mechanism to determine the functional O-mannosylation site on α-dystroglycan.

Rieko Imae, Naoyuki Kuwabara, Hiroshi Manya, Tomohiro Tanaka, Masato Tsuyuguchi, Mamoru Mizuno, Tamao Endo, Ryuichi Kato

Open access · bronzeAbstract read
In one paragraph

Article in Genes to cells : devoted to molecular & cellular mechanisms, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Rieko ImaeMolecular Glycobiology, Research Team for Mechanism of Aging, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Itabashi-ku, Japan.
Naoyuki KuwabaraHigh Energy Accelerator Research Organization (KEK), Institute of Materials Structure Science, Structural Biology Research Center, Tsukuba, Japan.
Hiroshi ManyaMolecular Glycobiology, Research Team for Mechanism of Aging, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Itabashi-ku, Japan.
Tomohiro TanakaLaboratory of Glyco-organic Chemistry, The Noguchi Institute, Itabashi-ku, Japan.
Masato TsuyuguchiHigh Energy Accelerator Research Organization (KEK), Institute of Materials Structure Science, Structural Biology Research Center, Tsukuba, Japan.
Mamoru MizunoLaboratory of Glyco-organic Chemistry, The Noguchi Institute, Itabashi-ku, Japan.
Tamao EndoMolecular Glycobiology, Research Team for Mechanism of Aging, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Itabashi-ku, Japan.
Ryuichi KatoHigh Energy Accelerator Research Organization (KEK), Institute of Materials Structure Science, Structural Biology Research Center, Tsukuba, Japan.ORCID https://orcid.org/0000-0003-2087-2896
High Energy Accelerator Research Organization · JPTokyo Metropolitan Institute of Gerontology · JPNoguchi Institute · JP

Funding

Japan Agency for Medical Research and Development 20am0101083j0004,17gm0810010h0202,21ek0109443h0002Japan Society for the Promotion of Science JP19H05648,JP17H03987,JP16K07284
6 · The paper itself

Abstract

Defects in the O-mannosyl glycan of α-dystroglycan (α-DG) are associated with α-dystroglycanopathy, a group of congenital muscular dystrophies. While α-DG has many O-mannosylation sites, only the specific positions can be modified with the functional O-mannosyl glycan, namely, core M3-type glycan. POMGNT2 is a glycosyltransferase which adds β1,4-linked GlcNAc to the O-mannose (Man) residue to acquire core M3-type glycan. Although it is assumed that POMGNT2 extends the specific O-Man residues around particular amino acid sequences, the details are not well understood. Here, we determined a series of crystal structures of POMGNT2 with and without the acceptor O-mannosyl peptides and identified the critical interactions between POMGNT2 and the acceptor peptide. POMGNT2 has an N-terminal catalytic domain and a C-terminal fibronectin type III (FnIII) domain and forms a dimer. The acceptor peptide is sandwiched between the two protomers. The catalytic domain of one protomer recognizes the O-mannosylation site (TPT motif), and the FnIII domain of the other protomer recognizes the C-terminal region of the peptide. Structure-based mutational studies confirmed that amino acid residues of the catalytic domain interacting with mannose or the TPT motif are essential for POMGNT2 enzymatic activity. In addition, the FnIII domain is also essential for the activity and it interacts with the peptide mainly by hydrophobic interaction. Our study provides the first atomic-resolution insights into specific acceptor recognition by the FnIII domain of POMGNT2. The catalytic mechanism of POMGNT2 is proposed based on the structure.

Indexed as

Catalytic DomainDystroglycansGlycosyltransferasesHumansMannoseProtein BindingDystroglycansGlycosyltransferasesMannosePOMGNT2 protein, humancore M3fibronectin type III domainglycosyltransferasemuscular dystrophyα-dystroglycanopathy

Identifiers

PMID33893702
PMCPMC8360118
OpenAlexW3155182970

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.